Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. David R. Spigel

Dr. David R. Spigel

Chief Scientific Officer

Medical oncologist Dr. David Spigel is the chief scientific officer at the Sarah Cannon Research Institute and a member of Tennessee Oncology, one of America’s largest community based groups of cancer-care specialists.

Get in touch
Jump to a Topic:

About David R. Spigel

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Board Certified icon

    Board Certified in Hematology

Get to Know Dr. David Spigel

Dr. David Spigel is a medical oncologist and chief scientific officer at the Sarah Cannon Research Institute, overseeing the innovative clinical trials that are advancing the treatment of malignant mesothelioma and many other cancers.

Spigel, who specializes in hematology, also is part of the community based Tennessee Oncology group in Nashville, where he sees patients at the TriStar Centennial Medical Center.

He has played a key role in the recent development of immunotherapy and other targeted medicines being developed at Sarah Cannon.

Spigel works closely with other cancer research leaders, along with pharmaceutical and biotech companies, to bring the latest advances from the laboratory into the clinic.

Although he handles all adult malignancies, he has special clinical interest in thoracic cancers, including lung cancer and mesothelioma. He also treats Hodgkin’s lymphoma, multiple myeloma and esophageal cancer.

Specialties of Dr. David Spigel

  • Pleural mesothelioma
  • Lung cancer
  • Adult malignancies
  • Clinical trials
  • Cancer research
  • Hematology

Dr. David Spigel’s Experience and Medical Education

  • Tennessee Oncology
  • Sarah Cannon Research Institute
  • Dana-Farber Cancer Institute (Fellowship)
  • Indiana University Medical Center (Residency)
  • University of Tennessee College of Medicine

Awards and Other Recognitions

  • Patient Safety Excellence Award
  • Medical oncology board certified
  • American Society of Clinical Oncology (Member)
  • American College of Physicians (Member)

Mesothelioma Clinical Trials Under David Spigel, M.D.

  • A phase I/II clinical trial to establish dosage levels and overall response rate using genetically engineered T-cells for patients with pleural mesothelioma and lung cancer expressing high levels of mesothelin.
  • Phase I/II clinical trial studying the use of INCB001158 as a single agent and in combination with an immune checkpoint inhibitor for patients with metastatic solid tumors, including mesothelioma.
  • A phase Ib/II clinical trial studying rebastinib in combination with carboplatin chemotherapy to assess safety and efficacy for patients with advanced or metastatic solid tumors, including mesothelioma cancer.

See More Top Mesothelioma Doctors

Publications of Dr. David Spigel

  • Horn, L., Spigel, D. et al. (2017, October 12). Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Journal of Clinical Oncology.
  • Spigel, D. (2013, November 10). Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology

Disclaimer: Dr. David R. Spigel has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Fran Mannino, editor for The Mesothelioma Center
Edited by

4 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Tennessee Oncology. (n.d.). David Spigel, M.D.
    Retrieved from:
  2. (2020, May 22). Phase 1/2 Trial of TC-210 T Cells in Patients with Advanced Mesothelin-Expressing Cancer.
    Retrieved from:
  3. (2020, March 20). A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors.
    Retrieved from:
  4. (2020, February 27). Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified July 28, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now